<DOC>
	<DOCNO>NCT02097745</DOCNO>
	<brief_summary>This study assess long-term safety efficacy repeat treatment MabThera , combination methotrexate steroid , patient previously randomize MabThera study WA17042 . The anticipated time study treatment Mabthera available local market target sample size 100-500 individual .</brief_summary>
	<brief_title>A Study Efficacy Safety Re-treatments With Rituximab Patients With Active Rheumatoid Arthritis Who Have Had Inadequate Response Anti-tnfa Therapies</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<criteria>adult patient 1880 year age active RA ; patient participate MabThera study WA17042 , complete least Week 24 visit ; eligible retreatment , base clinical symptom ; patient reproductive potential must use reliable contraceptive method . patient participate MabThera study WA17042 withdraw safety followup ; current treatment diseasemodifying antirheumatic drug ( apart methotrexate ) , antiTNFalfa , antiIL1 , biologic therapy ; development new contraindication receive MabThera ; woman pregnant breastfeeding .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>